Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL0704rP
- Development stage
- Discontinued
- Lead developer
- Allergopharma
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AL0704rP is a recombinant allergen immunotherapy developed by Allergopharma for the treatment of allergic rhinoconjunctivitis caused by timothy grass pollen. It consists of a mixture of five recombinant major allergens from timothy grass (*Phleum pratense*): rPhl p 1, rPhl p 2, rPhl p 5a, rPhl p 5b, and rPhl p 6. The therapy aims to induce immunological tolerance by shifting the immune response from a Th2-dominated allergic profile to a Th1/Treg-mediated profile, thereby reducing symptoms upon natural allergen exposure. Despite reaching Phase 3 clinical trials (e.g., the AMETHYST study), development was discontinued by the developer in 2017 following a strategic decision to exit the recombinant allergen field.
- Other names
- Recombinant Timothy Grass Pollen AllergensKeytruda-Allergopharma GmbH & Co. KG-allergic rhinoconjunctivitis
02
Targets
Group 5 grass pollen allergenPhl p (Timothy grass pollen allergen)EXPB1 (Group 1 beta-expansin)Phl p 6 (Timothy grass pollen allergen Phl p 6)
Beyond the preview
Go deeper on AL0704rP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL0704rP.